Literature DB >> 11886399

Plasma exchange as a source of protein C for acute onset protein C pathway failure.

Andy Hodgson1, Tom Ryan, Jan Moriarty, George Mellotte, Ciaran Murphy, Owen P Smith.   

Abstract

Severe bacterial sepsis, particularly secondary to meningococcaemia, is a well-recognized cause of purpura fulminans resulting from severe acquired protein C (PC) deficiency. Recently, PC and activated protein C (APC) concentrate replacement therapy has been shown to improve outcome in patients with meningococcaemia- associated purpura fulminans and severe sepsis respectively. Despite these impressive findings, PC and APC concentrates are not currently widely available. We describe a 31-year-old patient with pneumococcal septic shock, purpura fulminans (PF) and severe acquired PC deficiency, whom we successfully treated with conventional therapy and high-volume plasma exchange as a source of PC.

Entities:  

Mesh:

Year:  2002        PMID: 11886399     DOI: 10.1046/j.0007-1048.2002.03353.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

Review 1.  Plasma exchange therapy for thrombotic microangiopathies.

Authors:  Trung C Nguyen; Yong Y Han
Journal:  Organogenesis       Date:  2011-01-01       Impact factor: 2.500

2.  Case report: perioperative use of protein c concentrate for protein C deficiency in THA.

Authors:  Savyasachi C Thakkar; Michael B Streiff; Duane F Bruley; Simon C Mears
Journal:  Clin Orthop Relat Res       Date:  2009-12-10       Impact factor: 4.176

3.  Human protein C concentrate in the treatment of purpura fulminans: a retrospective analysis of safety and outcome in 94 pediatric patients.

Authors:  Alex Veldman; Doris Fischer; Flora Y Wong; Wolfhart Kreuz; Michael Sasse; Bruno Eberspächer; Ulrich Mansmann; Rudolf Schosser
Journal:  Crit Care       Date:  2010-08-19       Impact factor: 9.097

Review 4.  Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications.

Authors:  Joan T Merrill; Doruk Erkan; Jerald Winakur; Judith A James
Journal:  Nat Rev Rheumatol       Date:  2020-07-30       Impact factor: 20.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.